In an unconventional bid to widen access to insulin for Americans, a nonprofit announced plans Thursday to make and distribute the life-saving diabetes treatment at a low price.
Civica Rx, which was formed four years ago with philanthropic backing, expects to sell its own versions of three widely prescribed insulin brands at no more than $30 a vial, or $55 for a box of five pen cartridges, for people with or without insurance. The insulin will not become available until early 2024, though, while a manufacturing facility is completed and regulatory approvals are obtained.
“This is a life-sustaining medicine where the cost is prohibitively high for many people,” said Dan Liljenquist, senior vice president and chief strategy officer at Intermountain Healthcare, a hospital system based in Utah, and the Civica board chair. “And this is a market that hasn’t repaired itself and, in fact, has gotten worse. But you have to be a player in the market to fix the market.”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
